Cite

HARVARD Citation

    Kamei, J. et al. (2022). Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney. IJU case reports. 5 (3), pp. 199-202. [Online]. 
  
Back to record